Department of Medicine, Koc University School of Medicine, Istanbul, Turkey.
Division of Nephrology, Department of Internal Medicine, Suleyman Demirel University School of Medicine, Isparta, Turkey.
Int Urol Nephrol. 2021 Sep;53(9):1839-1849. doi: 10.1007/s11255-020-02704-7. Epub 2021 Jan 3.
Diuretic volume reduction continues to be the mainstay of congestive heart failure (CHF) management globally. However, diuretic resistance is a critical topic that lacks standardized evidence-based management guidelines accounting for mechanisms of diuretic resistance, renal function, and co-morbidities. Major healthcare utilization consequences result from this. The authors herein reconcile the definition of renal functional decline with emphasis on biomarker-driven assessment. Novel goal-directed treatment approaches are reviewed including hypertonic saline, acetazolamide, sodium-glucose transporter inhibition, sequential nephron blockade and Elabela-APJ axis targeting are reviewed, as well as percutaneous visceral splanchnic sympathectomy (converting a volume-focused to a distribution-focused paradigm).
利尿剂的容量减少仍然是全球充血性心力衰竭(CHF)管理的主要方法。然而,利尿剂抵抗是一个关键的话题,缺乏针对利尿剂抵抗机制、肾功能和合并症的标准化循证管理指南。这会导致主要的医疗保健利用后果。本文作者通过强调基于生物标志物的评估,协调了肾功能下降的定义。还回顾了新的目标导向治疗方法,包括高渗盐水、乙酰唑胺、钠-葡萄糖转运蛋白抑制、顺序肾单位阻断和 Elabela-APJ 轴靶向治疗,以及经皮内脏内脏交感神经切除术(将以容量为中心的方法转变为以分布为中心的方法)。